Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Price Target at $9.33

Sana Biotechnology, Inc. (NASDAQ:SANA) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokers that have covered the stock in the last year is $9.3333.

Several research firms recently issued reports on SANA. TD Cowen raised Sana Biotechnology to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Weiss Ratings raised Sana Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 23rd. Finally, Bank of America reduced their price objective on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 14th.

Sana Biotechnology Price Performance

SANA stock opened at $3.10 on Tuesday. The stock has a market capitalization of $928.02 million, a PE ratio of -4.08 and a beta of 2.12. Sana Biotechnology has a 52 week low of $2.61 and a 52 week high of $6.55. The firm has a 50 day moving average of $3.49 and a 200 day moving average of $3.35.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. On average, equities research analysts expect that Sana Biotechnology will post -0.72 earnings per share for the current year.

Hedge Funds Weigh In On Sana Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of SANA. Sequoia Financial Advisors LLC purchased a new position in Sana Biotechnology during the 2nd quarter worth approximately $54,000. WINTON GROUP Ltd purchased a new stake in shares of Sana Biotechnology in the 2nd quarter valued at $99,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Sana Biotechnology in the second quarter worth $359,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Sana Biotechnology by 22.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 284,472 shares of the company’s stock worth $993,000 after acquiring an additional 52,766 shares during the period. Finally, Hsbc Holdings PLC raised its holdings in shares of Sana Biotechnology by 55.1% during the second quarter. Hsbc Holdings PLC now owns 111,959 shares of the company’s stock worth $392,000 after purchasing an additional 39,765 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cells and gene therapies for the treatment of serious diseases. The company’s approach is designed to create therapeutic cells that can be delivered to patients without requiring individualized manufacturing, potentially broadening access to cell-based medicines.

Sana is developing technologies intended to address key challenges in cell and gene therapy, including immune rejection, targeted delivery of genetic material and the production of engineered cells at scale.